Advanced Search

 

Study ID Status Title Patient Level Data
116604 Active not recruiting PGx6039 PGx Investigation of Pyrexia in Subjects Receiving GSK2118436 Monotherapy
116610 Completed An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (ronacaleret; a calcium sensing receptor antagonist)
116615 Completed Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - capsules. Crossover, randomized, single dose, two treatments, two periods and two sequences with meal (breakfast) study
116617 Completed A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects who Smoke Cigarettes
116623 Completed A double-blind [sponsor unblinded], randomized, placebo-controlled, staggered-parallel study to investigate the safety, tolerability, and pharmacodynamics of GSK2890457 in healthy volunteers and subjects with type 2 diabetes
116626 Completed PGx364: An ADME pharmacogenetic investigation to evaluate the pharmacokinetic variability of GSK2190915 in subjects from Studies LPA111834, LPA112025, and LPA112356
116628 Completed A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
116635 Completed Genetic and phenotypic susceptibility analysis of influenza viruses isolated from hospitalised adult subjects treated with intravenous zanamivir in the phase II study NAI113678
116637 Completed PGx: Exploratory meta-analysis of transcriptomics data from the SB681323 and prednisolone single dose biomarker study in COPD patients
116640 Completed Development of read-outs to detect and characterise the early and adaptive immune responses in healthy, hepatitis B virus naive adults vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals’ Adjuvant System
116647 Completed An observer-blind study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ Non-typeable Haemophilus influenzae (NTHi) investigational vaccine (GSK2838497A) in current and former smokers
116663 Completed A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix/Influsplit SSW 2012/2013 in people aged 18 years and above
116664 Completed Immunogenicity and safety study of GSK Biologicals’ Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in adults aged 18 years and older Study Listed on ClinicalStudyDataRequest.com
116666 Completed An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666) Study Listed on ClinicalStudyDataRequest.com
116669 Completed RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder inhalers; ELLIPTA and DISKUS, in Adult Subjects with Chronic Obstructive Pulmonary Disease
116672 Completed Use of the 24-Hour Restless Legs Syndrome (RLS) Symptom Diary to Assess RLS Augmentation with Gabapentin Enacarbil: An Integrated Analysis from Five Studies
116678 Completed A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
116679 Completed A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis Study Listed on ClinicalStudyDataRequest.com
116681 Completed A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of losmapimod in Healthy Japanese Subjects. Study Listed on ClinicalStudyDataRequest.com
116684 Active not recruiting PGX6115: Genetic Effects on Different eltrombopag Exposure between Asians and Whites
116688 Completed Gabapentin Enacarbil in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome With and Without Severe Sleep Disturbance: an Integrated Analysis of Subjective and Novel Objective Sleep Endpoints from Two Studies
116689 Completed An integrated review to evaluate dose response of umeclidinium (GSK573719) administered once or twice daily in Subjects with COPD
116696 Recruiting Prevalence of patients infected with CCR5-tropic HIV-1 in Korea
116697 Completed Open-label study to evaluate the safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged 50 years or older
116698 Completed A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.